Dupuytren's disease (DD) is one of the most common connective tissue disorders among Caucasians of northern European extraction. 1 DD is a fi broproliferative disease affecting the palmar fascia, and may lead to permanent fl exion contracture of the digits. 1 In affected individuals, DD-like fi brosis can also be found over the knuckles (Garrod's pads), feet (Lederhose's disease) and penis (Peyronie's disease). 2 3 While surgical intervention is the mainstay of treatment for DD, there is a high recurrence rate post-surgery. 1 2 The aetiopathogenesis of DD remains unknown; however, a strong genetic component has been suggested. The evidence supporting this assertion includes increased family history, high Caucasian prevalence and reports of common occurrence in twins. 4 Several studies have attempted to identify the susceptibility genes to DD; however, to date no single gene has been confi rmed to contribute to DD with a fully elucidated mechanism. Environmental factors, including trauma, alcohol, smoking and associated disease, have also been suggested to contribute to DD. 1 The aim of this review is to summarise our current molecular understanding of DD, with a focus on fi ndings from global gene expression studies by: (1) carrying out meta-analysis on microarray datasets available in public repositories; (2) comparing genes reported to be dysregulated by more Whole genome and global expression profi ling of Dupuytren's disease: systematic review of current fi ndings and future perspectives B Shih, 1 S Watson, 2 A Bayat 1,2 than one global expression study or with more than one experimental technique; (3) comparing genes reported to be dysregulated and located within or adjacent to a genetic linkage in association with DD; and (4) signalling pathways suggested to be involved in DD by global expression profi ling/ meta-analysis.
CANDIDATE GENES IN META-ANALYSIS AND GLOBAL RNA EXPRESSION STUDIES
Eight global messenger RNA expression microarray studies [5] [6] [7] [8] [9] [10] [11] [12] and one microRNA profi ling 13 study were identifi ed (see supplementary table S1, available online only). Four sets of microarray data on DD were identifi ed at both the National Center for Biotechnology Information gene expression omnibus (GEO) and the European Bioinformatics Institute array express record ID for GEO: GSE4457, GSE2688, GSE21221 and GSE31356. Two of the datasets, GSE2688 12 and GSE4457, 6 were identical; therefore, the two datasets (and associated studies) were considered as one in the analysis of this review. GSE21221 10 involved the use of two experimental platforms on the same biological samples; the dataset from the CodeLink platform was selected for meta-analysis as the authors presented a higher number of signifi cantly dysregulated genes with the CodeLink platform in their publication. 10 A total of 7072 unique UniGene ID was included in the meta-analysis (see supplementary text, available online only, and fi gure 1).
Twenty-one genes have been reported with consistent regulation by multiple gene expression profi ling microarray studies (table 1 and fi gure 2). Nineteen of these 21 genes were assessed in the meta-analysis, 16 of which were also determined to show statistically signifi cant dysregulation in DD with the same regulation (over/underexpression) ( 10 and tenascin C (TNC) (table 1). 14 There is only one array-based microRNA profi ling study in DD. MicroRNA are post-transcriptional regulators that negatively regulate their mRNA targets. 17 Mosakhani et al 13 compared the microRNA profi les in their study with the mRNA expression profi les in the study by Forsman et al, 5 and showed concurrence on the downregulation of microRNA and upregulation of their target mRNA. 1) . Other than TGFB1, all of these genes were found to be signifi cantly upregulated in the meta-analysis (table 1). A total of 322 genes (out of 7072 analysed) was determined to be signifi cantly dysregulated in DD by the meta-analysis; 64 of the 322 genes demonstrated the same regulation as those reported by at least one gene expression microarray study (see  supplementary table S2 , available online only, and fi gure 1). Twenty-eight of these 64 genes share the same regulation as those seen in fi bromatosis, based on the expression data available in the gene expression atlas 18 (see supplementary table S2 , available online only, and fi gure 1).
COMPARING GLOBAL RNA EXPRESSION WITH PROTEIN EXPRESSION
Investigation of both mRNA and protein levels are necessary and complimentary for the identifi cation of biomarkers in human disease. 19 20 Two whole-proteome studies have been carried out to identify differentially expressed proteins in DD. 21 22 While O'Gorman et al 22 identifi ed three potential low molecular weight tissue protein markers that were positively associated with DD, the genes coding for these protein markers were not determined; therefore these fi ndings were not included in this review. By comparing biopsies of DD with internal palmar fascia, Kraljevic Pavelic et al 21 have reported 44 genes showing fi ve-fold upregulation in DD through two-dimensional gel electrophoresis. Of these genes, three were reported in mRNA expression profi ling microarrays with consistent regulation; ARHGDIA, 8 COL6A3 (meta-analysis) and TPM4. 11 ARHGDIA is also overexpressed in Peyronie's disease. 8 Several genes determined to be dysregulated by multiple gene expression microarrays have been validated at the protein level by immunohistochemistry, western blotting, or zymography, and include MMP2, 15 COL1A2 23 and POSTN. 11 POSTN demonstrates the highest consistency in its altered expression in DD; found to be dysregulated in three mRNA microarray studies, 8 9 11 and the meta-analysis in this review (derived from data in Lee et al, 6 Satish et al 10 and Zhang et al), 12 which also showed upregulation of POSTN. POSTN is an extracellular membrane protein that is found in collagen-rich connective tissues, 24 and overexpression of POSTN may contribute to tumorigenesis by promotion of cancer cell survival, epithelial-mesenchymal transition, invasion and metastasis. 25 Application of exogenous POSTN to fi broblasts derived from DD and control fascia was found differentially to regulate apoptosis, proliferation, alpha-smooth muscle actin expression and fi broblast populated collagen lattice contraction. 11 Protein staining for several extracellular matrix (ECM) proteins or growth factors in DD correlates to mRNA dysregulation reported in microarray studies. 9-12 26 27 Howard et al 27 demonstrated higher protein levels of fi bronectin in DD, also supported by mRNA microarray studies. 6 12 ECM surrounding alpha smooth muscle actin-positive cells in proliferative nodules demonstrate staining of type IV collagen, laminin and tenascin. 28 29 Several immunohistological studies investigate specifi c ECM in DD. [27] [28] [29] [30] Pathological collagen deposition has been associated with DD. 31 Collagens are triple helical proteins found in ECM, and there are more than 30 collagens and collagen-related proteins. 32 Early studies have noted an increase in the ratio of type III to type I collagen going from control palmar fascia through uninvolved, mildly involved cords to nodules of DD. 33 Murrell et Review group.bmj.com on January 7, 2013 -Published by ard.bmj.com Downloaded from al 34 suggested that this change in ratio is due to the inhibition of type I collagen expression at high fi broblast density. Conversely, type III collagen has not been suggested in global expression studies. Dysregulation in several collagen types has been suggested, including COL1A1, COL1A2, COL4A1, COL4A2, COL4A5, COL5A1, COL5A2, COL6A1, COL6A3, COL7A1, COL8A1, COL9A3, COL14A1 and COL15A1. Of these collagens; types I, IV and V are most consistent in their dysregulation in DD (table  1) . The fi brillar collagens; the major product synthesised by connective tissue cells, comprised fi ve members, collagen types I, II and III, V and XI, with the former three types being the quantitatively major types. 35 Collagen V is assembled together within single fi brils with collagen I. 36 Fibroblasts isolated from individuals with COL5A1 haplo-insuffi ciency suggest that the quantity of collagen fi brils deposited is highly sensitive to a reduction in type V collagen, despite being a minor collagen type. 37 Higher levels of tenascin protein have been observed in more aggressive forms of DD, 30 which is in agreement with upregulation of tenascin C mRNA and downregulation of microRNA targeting TNC. 9 13 14 Similarly, TGFB2 mRNA has been shown to be upregulated in DD, 12 and shows intense intracellular localisation within myofi broblasts in the proliferative and involutional stages of the disease. 26 Indeed, the addition of TGFB2 had a signifi cant effect on the development of myofi broblasts, a cell type thought to contribute to DD contracture. 26 38 
CORRELATING GENE EXPRESSION WITH LINKAGE AND GENOME-WIDE ASSOCIATION STUDIES
Several chromosomal regions have been associated with DD from genetic linkage and association studies, including comparative genomic hybridisation, [39] [40] [41] genome-wide family linkage, 42 and case-control whole genome association studies. 43 44 Genes within signifi cantly associated loci were compared with the differentially expressed genes reported in the gene expression profi ling studies. In this review, 2 genes, MAFB and protein kinase X-linked (PRKX), were found to be highlighted by both types of studies (fi gure 2). PRKX, which contains a single nucleotide polymorphism (SNP; rs17335275) that showed a positive association with DD, 44 is upregulated in DD. 7 Interestingly, PRKX contributes to angiogenesis, as it stimulates endothelial cell proliferation, migration and vascular-like structure formation. 45 The potential involvement of angiogenesis in DD pathogenesis was suggested by Gonzalez et al. 46 PRKX locates to the x-chromosome, while the DD WNT5A None n/a n/a 0.047/Up/1.4 miR-22, miR-30b, miR-494 ZIC1 None n/a n/a 0.003/Up/3.3 miR-101 *pfp, estimated percentage of false positive predictions. This is an equivalent to the false discovery rate or adjusted p values. RT-qPCR, reverse transcription quantitative PCR. †MicroRNA that are both dysregulated in Dupuytren's disease and predicted (using TargetScan) to target the genes indicated in the fi rst column are as given by Mosakhani et al. 13 RT-qPCR, reverse transcription quantitative PCR.
group.bmj.com on January 7, 2013 -Published by ard.bmj.com Downloaded from inheritance pattern has not been thought to be x-linked; a case with polyfi bromatosis including keloid scars and DD was reported to be x-linked. 47 The possible involvement of MAFB, a transcription factor that serves as a regulator of commitment and lineage determination of haematopoietic cells, has been extensively studied in DD. 6 13 48 49 MAFB is downstream of a SNP (rs8124695, showing a linkage)that has been shown to be positively associated with DD. 43 Both previous microarray studies and meta-analysis carried out in this review indicate upregulation of MAFB in DD at the mRNA level. 6 12 In addition, microRNA (miR-130b, miR29c and miR-301b) predicted to target MAFB are downregulated in DD. 13 Furthermore, Lee et al 6 have observed that while all control fascia are negative for MAFB, half of the DD tissues showed positive immunohistochemical staining for MAFB. Upregulation of MAFB is also observed in fi bromatosis (gene expression atlas). 18 While no gene copy number variations were found in DD by Kaur et al, 39 increased DNA copy numbers at chromosomes 7p14.1 and 14q11.2 have been reported in DNA extracted from nodules, when compared with DNA from blood of the same patient or external controls. 40 41 Secreted frizzled-related protein (SFRP)4 and MMP14 are found within 450 kB of these copy number alterations, and signifi cantly higher levels of SFRP4 and MMP14 expression were found in DD nodules. 40 In addition, SNP (rs16879765) that was shown in a genome-wide association study to be significantly associated with DD, is adjacent to SFRP4. 43 SFRP4 is a Wnt antagonist and inhibitor of the Wnt-β-catenin pathway; 50 its expression is associated with reduced scar size after ischaemic injury 51 and restricted tumour growth. 52 Genetic variations in the regulatory regions of genes can potentially result in altered protein levels. 53 Polymorphisms within microRNA binding sites in the 3′ untranslated region of candidate genes for colorectal cancer have been linked to colorectal cancer formation. 54 By comparing SNP reported to be signifi cantly associated with DD and microRNA dysregulated in DD, a SNP (rs4730775) 43 is found to be located within a predicted target site for miR-299-3p, 53 a microRNA found to be exclusively detected in the majority of DD fascia (compared with the minority that shows an expression profi le resembling the controls). 13 This SNP locates within the 3′ untranslated region Figure 2 Summary of genes that have been implicated in Dupuytren's disease pathogenesis by multiple genome-wide association or global expression studies. The fi gure indicates genes that have been reported by multiple genome-wide association studies or global expression studies (yellow block); these include genes that have been reported in DNA and RNA studies, multiple DNA studies, multiple RNA studies and RNA and protein studies (joined by solid lines). Out of these genes, those that have also been confi rmed by other gene-specifi c experimental approaches are indicated in the light blue box (joined by dotted lines).
Figure 3
Studies carried out on the major signalling pathways that have been proposed to contribute to Dupuytren's disease (DD). From molecular aberrances observed in DD, three pathways have been suggested in the literature to be involved in DD pathogenesis, including the Akt signalling pathway, Wnt/β-catenin signalling pathway and TGFB pathways. In addition, functional analysis and inhibition studies have been carried out for genes within, or downstream of, the TGFB pathway. The study type (whether the observed aberrances are based on DNA, RNA, protein or inhibition/ functional studies) is indicated by the colours, green, purple, blue and red. Molecules that have been studied by different methods (for example, TGFBR1 has been proposed to be aberrant at both DNA and RNA levels) have been labelled by two colours. Review group.bmj.com on January 7, 2013 -Published by ard.bmj.com Downloaded from of WNT2; however, the expression of WNT2 has not previously been reported to be abnormal. Further experiments investigating microRNA, associated SNP and protein expression for WNT2 in the same group of patients would be required before determining a functional role.
Finally, a higher level of iroquois homeoboxprotein 6 (IRX6) mRNA has been observed in DD nodules and fat tissue adjacent to DD. 1 14 IRX6 locates within a critical chromosomal region, where positive genetic linkage was previously reported in a Swedish family. 42 
PATHWAYS AND DD
Several signalling pathways have been suggested to be involved in DD in published global gene expression or genome-wide association studies, including TGFB signalling, 12 Akt signalling 21 and Wnt signalling 43 (see supplementary table S3 , available online only, and fi gure 3). In addition, genes identifi ed to demonstrate different regulation in this review (from published global gene expression studies and meta-analysis) have been used for pathway enrichment analysis using the KEGG orthology-based annotation system (KOBAs) 2.0, from which pathways associated with integrin from multiple databases were signifi cant (table 2). These signalling pathways are not mutually exclusive from each other; activation of one pathway may induce another, or cross-talk between two pathways may occur (fi gure 4). [55] [56] [57] [58] [59] 
INTEGRIN SIGNALLING PATHWAY
Integrins constitute a family of transmembrane receptors that mediates attachment between the (intracellular) cytoskeleton and (extracellular) ECM, allowing transduction of signals from outside to inside of the cells, and vice versa. 57 Cross-talk between integrin and growth factors, such as TGFB 57 and insulin-like growth factor 1 receptor (IGF1R) 60 (these two growth factors have been implicated in DD and other signalling pathways), have been implicated in both normal physiological and pathological processes. 57 60 Integrin β-1 (ITGB1) has been suggested to modulate mechanical stress-induced mitogen-activated protein (MAP) kinases, 61 which have been suggested to be involved in the pathogenesis of frozen shoulder. 62 ITGB1 has also been suggested to be upregulated in Peyronie's disease in the microarray data generated by Qian et al. 8 Immunohistochemical studies in DD nodules have shown α 5 β 1 integrin expression in highly cellular areas, where fi bronectin is expressed in ECM, of proliferative and involutional phases, but not in the hypocellular areas of the involutional phase or the fi brotic tissues of residual phases. 29 63 A higher level of α 2 integrin (p≤0.05, against internal control fascia) and α 5 integrin chains (p≤0.07, against external control fasica) has been observed in DD cord through fl uorescence activated cell sorting. 64 Fibronectin, which is involved in the integrin signalling pathway, is elevated in DD, as shown by multiple studies at both mRNA and protein levels. 27 65-67 Isoforms of fi bronectin, ED-A and ED-B, are found in the proliferative and involuational stage of DD. 67 Oncofetal glycosylated fi bronectin is found to be exclusively localised in the active proliferative nodule, where it co-localises with TGFB and basic fi broblast growth factor. 68 Higher levels of plasminogen activator, which is involved in the integrin cell surface interactions, have been shown in DD nodules. 69 
AKT SIGNALLING PATHWAY
IGF1R and v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (ERBB2) are both involved in the activation of the Akt signalling pathway, and through an integrated proteomic approach were implicated as biomarkers involved in the regulation of cell proliferation in DD. 21 Furthermore, POSTN, a gene that has been characterised to be dysregulated in DD in several studies, 8 9 11 14 has been suggested to promote metastatic growth of colon cancer by inducing cell survival via the Akt pathway. 70 Kraljevic Pavelic et al 21 have also demonstrated upregulated levels of total Akt and phosphorylated Akt in disease fascia when compared with internal control fascia. Activated Akt is involved in the regulation of cell proliferation, survival and metabolism. 71 Upregulation of RACK1, a key mediator of IGF1-induced Akt activation, 72 has been observed in DD, 72 as well as overexpression of downstream targets of Akt signalling, including valosin containing protein (VCP), p21waf1/cip1 and tumor protein p53 (fi gure 3). 21 
TGFB SIGNALLING PATHWAY
Involvement of TGFB in DD has been suggested by several earlier studies (fi gure 3). 26 68 73 Aberrant TGFB expression has been reported to contribute to the formation of excessive tissue fi brosis. 74 Dysregulated levels of TGFBR3 and TGFB2 mRNA have been reported in microarray studies. 9 12 A polymorphism (rs17731) in the Zf9 transcription factor gene (KLF6), a transcription factor that increases TGFB1 expression, has been positively associated with DD in a case-control association study. 75 A polymorphism in the promoter of TGFB receptor 1 shows a signifi cant difference in genotype frequency between DD cases and a control population if the disease model is assumed to be recessive. 76 A recent study by Krause et al 23 indicated the involvement of the TGFB pathway in DD. Elevated expression and activation of the downstream molecules of TGFB have previously been reported, which include the SMAD pathway and the extracellular signalregulated kinase (ERK) MAP pathway. 23 TGFB has been shown to induce bimodal proliferation in connective tissue cells through regulation of platelet-derived growth factor (PDGF), 77 which has been implicated in DD. 23 78 Treatment with inhibitors of TGFB, the PDGF receptors and the MAP kinase pathway result in the decreased expression of fi brotic and proliferation markers. 23 Different isoforms of TGF-β have been reported to have both profi brotic and antifi brotic effects. TGFB1 is thought to be profi brotic, while TGFB3 is antifi brotic. However, the profi brotic or antifi brotic effects of TGFB2 remain contradictory; 79 while diminished TGFB2 production has been observed to lead to increased expression of profi brotic procollagen α 2 type 1 messenger RNA in an animal model of systemic sclerosis, 80 the addition of TGFB2 antibodies reverses the increased contraction on the fi broblast populated collagen lattice by keloid fi broblasts treated with exogenous TGFB2. 81 β-CATENIN AND WNT SIGNALLING PATHWAY Aberrant levels of β-catenin have been noted in DD, which is also supported by microRNA profi ling studies (fi gure 3). Varallo et al 82 showed high levels of β-catenin protein in the diseased fascia, whereas almost no expression is found in the control fascia. Neither genotypes nor DD recurrence could be associated with β-catenin overexpression. 82 83 Varallo et al 82 did not identify any mutations in the β-catenin in association with DD.
β-Catenin is a central component of the canonical Wnt signalling pathway, which infl uences cell survival and proliferation. 84 It has been suggested that the overexpression of β-catenin may be as a result of alterations in the Wnt signalling pathway. O'Gorman et al 85 investigated the gene expression of 13 Wnt molecules using microarray data and competitive reverse transcription PCR analysis and concluded that changes in Wnt expression were unlikely to be the cause of β-catenin dysregulation. However, O'Gorman et al 85 acknowledge that this does not rule out the potential involvement of altered Wnt signalling in DD pathogenesis; other genes involved in the Wnt pathway may be dysregulated, such as SFRP1, which demonstrated a consistently reduced level of expression in DD in their microarray data and in the meta-analysis carried out here. Downregulation of SFRP1 in mammary epithelial cells results in increased sensitivity to TGFB signalling, 86 which would also tie in with the involvement of the TGFB pathway observed in DD (as discussed previously).
A recent genome-wide association study has revealed six different DD risk loci containing genes, which are involved in the Wnt signalling pathway, and include WNT4 (rs7524102), WNT2 (rs4730775), R-spondin 2 (RSPO2) (rs611744), WNT7B (rs6519955), SFRP4 (rs16879765) and sulfatase 1 (SULF1) (rs2912522). 43 In addition, microRNA predicted to target WNT5A and ZIC1 have been shown to be downregulated in DD cord, 13 which coincides with the overexpression of WNT5A and ZIC1 mRNA observed in the meta-analysis in this review as well as analysis of mRNA microarray data of Forsman et al 5 (comparisons made by Mosakhani et al). 13 Higher levels of WNT5A have been observed in the β-cateninaccumulating involutional zones in comparison with proliferative and residual zones. 83 ZIC1 and β-catenin co-expression have been described in DD myofi broblasts. 87 Receptor tyrosine kinase-like orphan receptor 2 (ROR2), which was demonstrated Review group.bmj.com on January 7, 2013 -Published by ard.bmj.com Downloaded from to be upregulated in DD at both protein and mRNA levels, was shown to be involved in osteoclastogenesis, 5 88 and is considered a potential biomarker for leiomyosarcoma and gastrointestinal stromal tumours. 89 In addition, WNT5A-ROR2 signalling has been suggested to be necessary for the expression of MMP13 during the development of cartilaginous tissue; MMP13 is also overexpressed in DD. 90 91 Androgen receptors (AR), which interact with β-catenin and promote Wnt signalling at the chromatin level, 92 have been reported to be elevated and co-localise with α-smooth muscle actin in DD cultures and DD tissue. 93 Testosterone or dihydrotestosterone, which is converted from testosterone, activates AR; the involvement of AR may explain a male predominance that has been seen in DD. 93 AR mRNA levels, however, were reported to be signifi cantly underexpressed by Satish et al 10 and the metaanalysis carried out here. While implication of the Wnt and β-catenin signalling pathways in the aetiology of DD has been reported by several studies through different techniques (fi gure 3), detailed analysis of the downstream components and targets of the Wnt pathway in vitro would be required to elucidate its involvement in DD. 94 
CONCLUSIONS AND FUTURE PERSPECTIVES
Whole genome association studies and global gene expression studies that have investigated polymorphisms, transcript or protein expression across the entire genome have provided data regarding genes that may be involved in DD, through altered gene expression or genotype associations. The initial analysis of these data created large lists of affected genes of potential interest, some with unknown biological function and relevance to DD. Interpreting these data continues to be a challenging task, but this effort has led to the identifi cation of potential biomarkers involved in DD formation. However, these fi ndings can also potentially lead to overinterpretations, whereby the observed molecular aberrances may not be truly aetiological. 95 Rehman et al 95 proposed a complex model for DD, involving simultaneous occurrences of aberrances in several networks, each consisting of internal factors, like genetic background and environmental factors, such as trauma and alcohol consumption (fi gure 4). A limited number of studies exist that have characterised the molecular differences that may arise from environmental factors, and compared differences between mild and severe forms of DD. Isometric tension on DD and control cells has been demonstrated to show a differential effect on β-catenin and fi bronectin expression. 66 The MMP expression profi le has also been associated with clinical outcome. 96 Further research on these areas may help elucidate the varying degrees of phenotypic severity observed in DD.
In conclusion, this review has described genes and pathways that have been identifi ed to be involved in DD through whole genome and global gene expression studies, and highlighted genes that have been suggested to be involved in DD pathogenesis by detailed analysis of these previous studies. Further characterisation of functions and pathways in these genes, and investigation of the interaction between these pathways, may help in better understanding and elucidation of DD pathogenesis.
